RedHill Biopharma (RDHL) – Globe Newswire
-
Proactive news headlines including Royal Wins Corp, MAS Gold, NEO Battery, Enveric Biosciences and Champion Gaming
-
Avalo Appoints Two New Independent Directors to Its Board
-
Proactive news headlines including Facebook, Globex Mining Enterprises, Ridgeline Minerals, Else Nutrition Holdings and Railtown AI Technologies
-
Proactive news headlines including BioHarvest Sciences, Kontrol Technologies, Willow Biosciences, GameSquare Esports and Pure Gold Mining
-
Proactive news headlines including Bitcoin, Lucky Minerals, Kintara Therapeutics, Ayurcann Holdings, Melkior Resources and Altiplano Metals
-
Proactive news headlines including AIM ImmunoTech, RedHill Biopharma, KWESST, Universal Ibogaine and Else Nutrition
-
Proactive headlines including Amryt Pharma, Neo Battery, Belmont Resources, Bhang and Mason Graphite
-
Proactive headlines including Bitcoin, ESE Entertainment, Gatling Exploration, Redhill Biopharma and Adyton Resources
-
Proactive news headlines including Gevo, Tocvan Ventures, Mindset Pharma, Kootenay Silver and Pathway Health
-
Proactive news headlines including Endeavour Mining, PayPal, Alternus Energy, Phunware, Todos Medical and Orgenesis
-
Proactive headlines including Alpine 4 Holdings, FPX Nickel Corp and RedHill Biopharma
-
Proactive headlines including Alpine 4 Holdings, FPX Nickel Corp and RedHill Biopharma
-
Proactive news headlines including The Parent Company, Phunware, Plurilock Security and Hannan Metals
-
Proactive news headlines including The Parent Company, Phunware, Plurilock Security and Hannan Metals
-
Proactive news headlines including Royal Road Minerals, Great Panther Mining, PharmaDrug, Codebase Ventures and Nextech AR Solutions
-
Proactive news headlines including Royal Road Minerals, Great Panther Mining, PharmaDrug, Codebase Ventures and Nextech AR Solutions
-
Proactive news headlines including Silver Range Resources, Vuzix Corp, Endeavour Mining and Delta 9 Cannabis
-
Proactive news headlines including Silver Range Resources, Vuzix Corp, Endeavour Mining and Delta 9 Cannabis
-
Annual Changes to the Nasdaq Biotechnology Index
-
RedHill Biopharma to Present at German Equity Forum 2020
-
RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
-
RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
-
RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020
-
RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination
-
RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication
-
RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
-
RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib
-
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
-
RedHill Biopharma’s Opaganib COVID-19 Study Passes Second Independent Committee Review
-
RedHill Biopharma to Present at BIO Investor and BIO-Europe 2020 Virtual Conferences
-
Brazil Approves RedHill Biopharma’s Phase 2/3 COVID-19 Study with Opaganib
-
RedHill to Present at the Morgan Stanley Annual Global Healthcare Conference and Additional September Events
-
RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
-
RedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania
-
RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
-
RedHill Biopharma Provides Q2/2020 Financial Results and Operational Highlights
-
RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products
-
RedHill Biopharma to Host Second Quarter Financial Results and Business Highlights Conference Call and Webcast on August 13, 2020
-
RedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico
-
RedHill Biopharma to Participate in Upcoming BTIG and Intellisight Conferences
-
RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®
-
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
-
RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19
-
RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology
-
RedHill Biopharma Increases Patient Access to Talicia® with EnvisionRx Formularies
-
RedHill Biopharma Accelerates Phase 2/3 COVID-19 Program with Addition of Brazil and Mexico
-
RedHill Biopharma Seeks SEC Review of Suspicious Trading Activity
-
RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia
-
RedHill Biopharma to Present at the Sachs Novel Coronavirus Investment Forum
-
RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK
Back to RDHL Stock Lookup
